
Opinion|Videos|April 4, 2025
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Panelists discuss how to optimize treatment outcomes by managing the transition from biologics to JAK inhibitors and considering dose adjustment strategies when patients show inadequate response to initial therapy.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5
















